Investment Analysts’ Weekly Ratings Updates for Zimmer Biomet (ZBH)

A number of firms have modified their ratings and price targets on shares of Zimmer Biomet (NYSE: ZBH) recently:

• 7/25/2026 – Zimmer Biomet was upgraded by Wall Street Zen from “hold” to “buy”.
• 7/20/2026 – Zimmer Biomet was downgraded by Weiss Ratings from “hold (c-)” to “sell (d+)”.
• 7/8/2026 – Zimmer Biomet is now covered by BMO Capital Markets. They set a “market perform” rating and a $95.00 price target on the stock.
• 7/8/2026 – Zimmer Biomet was upgraded by BMO Capital Markets to “hold”.
• 7/6/2026 – Zimmer Biomet had its “hold (c-)” rating reaffirmed by Weiss Ratings.
• 7/4/2026 – Zimmer Biomet was downgraded by Wall Street Zen from “buy” to “hold”.
• 5/28/2026 – Zimmer Biomet had its price target lowered by Citigroup Inc. from $95.00 to $93.00. They now have a “neutral” rating on the stock.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Thursday, June 25th will be paid a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 1.1%. The ex-dividend date is Thursday, June 25th. Zimmer Biomet’s dividend payout ratio is 24.94%.

Insider Activity

In related news, insider Sang Yi sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $82.64, for a total transaction of $413,200.00. Following the completion of the sale, the insider directly owned 27,251 shares in the company, valued at approximately $2,252,022.64. The trade was a 15.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 1.28% of the company’s stock.

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.